Jefferies Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-2,781
| Closed | -$354K | – | 1742 |
|
|
2021
Q4 | $354K | Buy |
2,781
+99
| +4% | +$13K | ﹤0.01% | 1262 |
|
|
2021
Q3 | $349K | Buy |
2,682
+1
| +0% | +$151 | ﹤0.01% | 1340 |
|
|
2021
Q2 | $476K | Sell |
2,681
-12,619
| -82% | -$2.19M | ﹤0.01% | 1185 |
|
|
2021
Q1 | $2.51M | Buy |
15,300
+8,935
| +140% | +$1.47M | 0.02% | 597 |
|
|
2020
Q4 | $1.05M | Buy |
+6,365
| New | +$948K | 0.01% | 931 |
|
|
2020
Q2 | – | Sell |
-2,255
| Closed | -$225K | – | 1682 |
|
|
2020
Q1 | $225K | Buy |
+2,255
| New | +$292K | ﹤0.01% | 1645 |
|
|
2019
Q2 | – | Sell |
-5,364
| Closed | -$767K | – | 2694 |
|
|
2019
Q1 | $767K | Buy |
5,364
+3,231
| +151% | +$421K | 0.01% | 1405 |
|
|
2018
Q4 | $264K | Sell |
2,133
-8,667
| -80% | -$1.29M | ﹤0.01% | 1709 |
|
|
2018
Q3 | $1.82M | Buy |
10,800
+4,615
| +75% | +$794K | 0.01% | 1033 |
|
|
2018
Q2 | $1.07M | Buy |
6,185
+3,177
| +106% | +$519K | 0.01% | 1220 |
|
|
2018
Q1 | $454K | Sell |
3,008
-300
| -9% | -$44K | ﹤0.01% | 1552 |
|
|
2017
Q4 | $445K | Buy |
3,308
+1,700
| +106% | +$236K | ﹤0.01% | 1788 |
|
|
2017
Q3 | $235K | Sell |
1,608
-31,222
| -95% | -$4.72M | ﹤0.01% | 1995 |
|
|
2017
Q2 | $5.11M | Buy |
32,830
+19,622
| +149% | +$3M | 0.03% | 518 |
|
|
2017
Q1 | $1.92M | Buy |
+13,208
| New | +$1.72M | 0.01% | 938 |
|
|
2016
Q4 | – | Sell |
-8,333
| Closed | -$1.01M | – | 2342 |
|
|
2016
Q3 | $1.01M | Buy |
8,333
+3,261
| +64% | +$440K | 0.01% | 1274 |
|
|
2016
Q2 | $717K | Sell |
5,072
-6,742
| -57% | -$994K | ﹤0.01% | 1272 |
|
|
2016
Q1 | $1.54M | Sell |
11,814
-5,867
| -33% | -$730K | 0.01% | 964 |
|
|
2015
Q4 | $2.48M | Sell |
17,681
-35,150
| -67% | -$4.87M | 0.01% | 778 |
|
|
2015
Q3 | $7.02M | Buy |
52,831
+41,061
| +349% | +$7.07M | 0.04% | 362 |
|
|
2015
Q2 | $2.07M | Sell |
11,770
-26,514
| -69% | -$4.76M | 0.01% | 895 |
|
|
2015
Q1 | $6.62M | Buy |
38,284
+19,621
| +105% | +$3.37M | 0.04% | 334 |
|
|
2014
Q4 | $3.06M | Buy |
+18,663
| New | +$3.1M | 0.02% | 565 |
|
|
2014
Q3 | – | Sell |
-9,088
| Closed | -$1.4M | – | 2272 |
|
|
2014
Q2 | $1.34M | Buy |
9,088
+7,322
| +415% | +$1.02M | 0.01% | 785 |
|
|
2014
Q1 | $245K | Sell |
1,766
-1,580
| -47% | -$238K | ﹤0.01% | 1626 |
|
|
2013
Q4 | $423K | Buy |
+3,346
| New | +$346K | ﹤0.01% | 1220 |
|
|
2013
Q3 | – | Sell |
-15,619
| Closed | -$1.07M | – | 2057 |
|
|
2013
Q2 | $1.07M | Buy |
+15,619
| New | +$955K | 0.01% | 744 |
|
Other funds holding JAZZ
PCM
Jefferies Group's JAZZ Position: Q1 2022 in Review
Jefferies Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 2,781 shares — an estimated $354K sold.
Jefferies Group first reported a position in JAZZ in Q2 2013 and held it in 27 quarters. The position peaked at $7.02M in Q3 2015. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.
- Jefferies Group reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Jefferies Group sold 2,781 Jazz Pharmaceuticals shares in Q1 2022, an estimated $354K.
- Jefferies Group first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Jefferies Group's Jazz Pharmaceuticals position peaked at $7.02M in Q3 2015.
- 462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.
Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.